Eduardo Cunchillos
DVM
Founder and managing director of INNOQUA
Eduardo earned his Diplomate in Veterinary Medicine (DVM) degree at the University of Zaragoza (Spain), then obtained the Expert in Toxicology Master in Sevilla University, and he is a EUROTOX registered toxicologist (ERT) since 2005.
Eduardo started his career as study director and project leader working for pharmaceutical companies (Almirall, Vita), where he was intensively involved in the running of toxicological sub-acute, chronic, reproductive and carcinogenicity studies. This experience has given Eduardo a thorough knowledge of the experimental, scientific and interpretative aspects of nonclinical development.
In 2004, Eduardo became an independent consultant and founded Innoqua. Since then, he has provided advice to more than 250 pharmaceutical, biotechnology and medical device companies on their tailored toxicology and nonclinical programs, to ensure they met global regulatory requirements.
This included the interpretation of toxicological issues, preparing regulatory dossiers, gap analyses, due diligence activities, the critical review of safety issues requesting scientific advice (EMA, FDA and European national agencies), and the management and monitoring of toxicology studies.
Ana Andrés
BSc, PhD
Ana has more than 15 years of experience in the pharmaceutical sector and in national and international research projects. She holds a degree in Biology (Genetics, University of Barcelona) and a PhD in Biochemistry and Molecular Biology (Autonomous University of Barcelona).
Following the postdoctoral research, she started working in the Pharmaceutical industry as study director in Predictive Toxicology, setting up new methodologies and study designs, contributing with project managers and scientific committees for early drug characterization.
Since 2015, Ana has become a nonclinical and toxicology consultant at Innoqua in pharmaceutical, biotechnology, veterinary, chemical, food and environmental fields, involved in the design of nonclinical strategies for development of new drugs, monitoring safety and toxicology studies and liaising between companies and Contract Research Organizations (CRO’s) all around Europe and USA, preparing and reviewing nonclinical documents for regulatory submissions and interacting with regulatory Authorities, as well as making safety assessments and reports in different toxicology areas. This has equipped her with a broad vision and strong background on drug safety, nonclinical study monitoring and regulatory strategies within multiple therapeutic areas.
Juan Román
BSc, PhD
Juan has extensive experience in different areas of Pre-clinical development of medicinal products from both Pharmaceutical industry and global preclinical CROs. He holds a degree in Biology (University of Barcelona). Then he earned his PhD in Biology in the school of medicine (Hospital Clínic, University of Barcelona) studying the molecular mechanisms involved in the liver disease in a translational medicine setting.
Following PhD, Juan joined the pharmaceutical company Grupo Uriach where he was involved in different research projects. After this, he was Team leader in Palau Pharma in a research program of autoimmunity aimed at developing kinase inhibitors for the treatment of autoimmune diseases. Afterward, Juan worked at Envigo as Cellular Immunology Scientist and he liaised with toxicology project leaders and other scientists to optimize project proposals and provide expertise in a clear, concise and timely manner. He was Toxicology Study Director in Anapath Research for more than two years where he participated in the development of various new medicines (biologics and small molecules). Juan joined Innoqua as nonclinical and toxicology consultant in January 2025.
We also count on the collaboration of a broad network of nonclinical experts covering multiple specialization areas as needed by our customers.